Dualyx specializes in the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company focuses on creating immune modulators, particularly Treg-targeted therapies, which are designed to suppress unwanted autoimmune reactions in patients. By advancing these innovative treatments, Dualyx aims to provide lasting solutions for individuals suffering from autoimmune diseases, ultimately enabling medical professionals to offer effective cures.
Operator of a microbiome research firm intended to transform microbiome research, diagnostics and therapeutics. The company delivers a high-throughput low-cost platform for dynamic and real-time analysis and quantification of the human gut microbiome, offering informed precision diagnostics and targeted therapies, enabling patients to improve their lives through novel approaches to lead a healthy life.
GS Bavaria specializes in the manufacturing of industrial-scale nano-sized carbide powders, focusing on environmentally friendly nanomaterials. The company utilizes a revolutionary bioleaching extraction process that transforms hard metal scrap into tungsten and tungsten carbide nanoparticles. This innovative method not only enables cost-efficient production but also minimizes energy consumption, making it a sustainable alternative in the industry. By harnessing the capabilities of bacteria, GS Bavaria positions itself to expand its processes to other metals in the future, offering unique materials and functional additives to clients across various sectors.
Invasight is a clinical biotech company that focused on revolutionizing cell invasion research. The company was founded in 2019 and is headquartered in Zurich, Switzerland.
Noscendo GmbH is a diagnostics company based in Duisburg, Germany, specializing in bioinformatics solutions for identifying and assessing pathogens associated with bloodstream infections. Their diagnostic procedures utilize Next Generation Sequencing (NGS) technology, enabling intensive care clinicians to detect bacteria, fungi, viruses, and parasites present in patients' blood. Noscendo employs proprietary algorithms to evaluate the significance of each identified pathogen, thereby enhancing the accuracy and effectiveness of infection management in clinical settings.
Lindis Blood Care is focused on enhancing the outcomes of cancer surgeries through the development of a medical device that removes cancer cells from salvaged blood. This innovation facilitates the possibility of autologous blood transfusions, allowing cancer patients to receive their own blood collected during surgery. By enabling self-blood administration, Lindis Blood Care aims to improve the safety and effectiveness of blood transfusions for patients undergoing tumor removal, ultimately supporting better recovery and health outcomes.
Nebula Biocides specializes in the development of innovative disinfection solutions aimed at effectively combating persistent bacterial spores and resistant viruses. The company focuses on creating application-oriented disinfection products that provide reliable protection against infections in various settings. Their offerings include advanced disinfection systems and devices designed to ensure comprehensive microbial control, addressing the challenges posed by stubborn pathogens. Through these solutions, Nebula Biocides aims to enhance health safety for users by delivering effective disinfection that can be utilized in diverse environments.
Computomics is a team of world-leading experts in plant research and bioinformatics, offering next-generation sequencing (NGS) analyses for agriculture biotech companies and crop scientists. Whether you are concerned with crop improvement, seed production or plant protection, Computomics helps navigate the complexities of grain, vegetable, fruit and other genomes. Our advanced bioinformatics services provide our customers with quality NGS data interpretation from state-of-the-art genomics tools and technologies. Let us help you achieve your research goals.
Abalos Therapeutics GmbH is a biotechnology company based in Essen, Germany, focused on developing innovative immuno-oncology therapeutics. Founded in 2019, the company specializes in arenavirus-based drug candidates aimed at stimulating immune responses to target primary tumors and metastases. Utilizing its proprietary Fast Evolution platform, Abalos Therapeutics generates virus strains with optimized anti-tumoral properties. The company's approach involves reprogramming the immune system to effectively identify and eliminate malignant tumor tissue, thereby offering potential new treatment options for cancer. Through its novel immuno-virotherapy, Abalos Therapeutics seeks to harness the full capabilities of the immune system specifically against cancer cells.
FarmInsect GmbH, founded in 2019 and located in Bergkirchen, Germany, specializes in automated insect breeding systems designed to support sustainable animal husbandry. The company’s innovative machine and IoT technology facilitate local insect fattening, allowing farmers to produce insect larvae that serve as protein-rich feed for chickens, pigs, and fish. By utilizing organic residues to generate larvae, FarmInsect helps reduce reliance on imported soy and fishmeal, enabling farmers to consistently obtain young larvae on a weekly basis. This approach not only enhances efficiency in animal feed production but also promotes regional insect breeding, contributing to the overall sustainability of farming practices.
Provider of advanced materials intended to produce bioplastic film, plastics, and coatings from agriculture residues. The company's technology uses food production residues to produce materials that are compostable under natural composting conditions and provides a marketable product from agricultural residues such as starch or brewery residues as a raw material for home compostable, harmless for the environment and humans, enabling the society to get rid of the plastic materials that lead to serious environmental, marine pollution and lower carbon emissions.
PreComb is a technology company focused on enhancing cancer treatment outcomes through innovative solutions tailored for difficult-to-treat cancers. The company has developed a 3D drug testing technology that utilizes automated microtumor-based profiling for in vitro cancer diagnosis. This technology enables clinical institutions to conduct on-site evaluations, allowing for the functional assessment of various cancer drugs, combinations, and concentrations using patient-derived micro-tumors. By optimizing the selection of therapies, PreComb aims to improve success rates in cancer treatment and ultimately enhance the quality of life for patients.
Developer of a cell therapy technology designed for the treatment of patients after a stem cell transplant to prevent rejection reactions. The company's technology focuses on the development of clinical testing of cell therapeutics for the suppression of transplant rejection and autoimmunity and the portfolio of cell therapy, enabling patients to prevent the fatal consequences of rejection, significantly improving their quality of life, and also opening up to many therapy options.
GeneQuine Biotherapeutics designs and develops gene therapies for its clients. The therapies developed by the company aim to treat osteoarthritis. Its product portfolio consists of GQ-201, GQ-202, and GQ-203. GeneQuine Biotherapeutics was founded in 2011 by Stanislav Plutizki and Kilian Guse.
In Lignopure we produce natural degradable biopolymers from non-food sources. Our Lignopure product is the best-of-its-kind lignin, with proven non cytotoxicity and added functionality. No other lignin in the market can offer the safety of Lignopure and the tailored properties achieved through our protected technology. From the raw material production, we are able to deliver tailored lignin for different applications; these include particles for cosmetics, pharmaceuticals and food supplements. Additionally, our biobased prototypes include insulating materials, biobased polyurethane foams, aerogels and filaments for 3D printing.
stimOS GmbH develops a drug delivery biochemical procedure that initiates bone formation, anti inflammatory activity, and healing process. The company also develops technologies and procedures that refine, functionalize, and activate implant materials. It also offers research and development of implant materials and implant surfaces. stimOS GmbH was founded in 2015 and is based in Constance, Germany.
LOEWI is a scientific spin-off of the Technical University of Munich and pursues the vision of making personalized health and nutrition available to everyone. In doing so, LOEWI stands for a healthy and active lifestyle in order to optimally support the individual health of customers and patients. With a strong scientific focus, LOEWI enables data-driven personalization based on evidence-based methods that have been developed and tested in competitive sports over the last twelve years. LOEWI promotes the analysis of individual nutrient needs and supports the achievement of your full potential through highly personalized products and recommendations. The unique combination of science and technology is a cornerstone of LOEWI’s corporate culture. Building on this, LOEWI cooperates with leading universities and research institutions to actively promote the development of the industry.
Noscendo GmbH is a diagnostics company based in Duisburg, Germany, specializing in bioinformatics solutions for identifying and assessing pathogens associated with bloodstream infections. Their diagnostic procedures utilize Next Generation Sequencing (NGS) technology, enabling intensive care clinicians to detect bacteria, fungi, viruses, and parasites present in patients' blood. Noscendo employs proprietary algorithms to evaluate the significance of each identified pathogen, thereby enhancing the accuracy and effectiveness of infection management in clinical settings.
Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that serve as a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, focusing particularly on transcriptomics. By enabling single-cell barcoding in a test tube format, Scipio Bioscience's products facilitate advanced research in single-cell analysis, supporting laboratories in their scientific endeavors.
Biograil, established in 2019 and led by CEO Karsten Lindhardt, specializes in developing a medical device that aims to enhance drug delivery systems. The device, produced through injection molding, is designed to fit within a standard-sized capsule and delivers active substances directly into the gastrointestinal wall. By utilizing the body's natural peristaltic forces, Biograil's technology eliminates the need for mechanical moving parts, allowing for a more efficient and pain-free administration of biologics. This innovative approach addresses the common challenges associated with traditional injection systems, offering a promising alternative for patients requiring medication.
Lindis Blood Care is focused on enhancing the outcomes of cancer surgeries through the development of a medical device that removes cancer cells from salvaged blood. This innovation facilitates the possibility of autologous blood transfusions, allowing cancer patients to receive their own blood collected during surgery. By enabling self-blood administration, Lindis Blood Care aims to improve the safety and effectiveness of blood transfusions for patients undergoing tumor removal, ultimately supporting better recovery and health outcomes.
VEROVACCiNES GmbH, a biopharmaceutical company, develops novel types of vaccines that protect animals against infectious diseases. The company was founded in 2017 and is based in Halle, Germany.
Draupnir Bio is focused on developing innovative cholesterol-lowering medications aimed at preventing blood clots in the heart with greater efficacy than existing treatments. The company utilizes a platform that explores the glycome to create novel therapeutics, employing advanced techniques in array technology, protein chemistry, and carbohydrate chemistry. This platform enables the synthesis, screening, and selection of potent heparan sulfate glycomimetic drug candidates, targeting cardiovascular, inflammatory, and infectious diseases. Additionally, Draupnir Bio's technology includes the development of protein degraders that can target extracellular disease proteins, potentially addressing a wide range of unmet therapeutic needs across various medical conditions. This approach promises more convenient and accessible treatment options compared to traditional injectable therapies.
Abalos Therapeutics GmbH is a biotechnology company based in Essen, Germany, focused on developing innovative immuno-oncology therapeutics. Founded in 2019, the company specializes in arenavirus-based drug candidates aimed at stimulating immune responses to target primary tumors and metastases. Utilizing its proprietary Fast Evolution platform, Abalos Therapeutics generates virus strains with optimized anti-tumoral properties. The company's approach involves reprogramming the immune system to effectively identify and eliminate malignant tumor tissue, thereby offering potential new treatment options for cancer. Through its novel immuno-virotherapy, Abalos Therapeutics seeks to harness the full capabilities of the immune system specifically against cancer cells.
Vacis B.V. is a tissue engineering company based in Geleen, the Netherlands, founded in 2016. The company specializes in developing in situ tissue-engineered blood vessels aimed at improving vascular access for patients undergoing hemodialysis. Vacis's innovative technology involves the use of a synthetic rod that is implanted under the skin, prompting the body to generate a tissue capsule that matures into a functional blood vessel. This approach allows for the creation of autologous graft vessels, which offer enhanced patency and a reduced risk of complications compared to traditional prosthetic grafts. By providing novel therapeutic solutions for vascular surgery, Vacis addresses significant challenges in the field, including the frequent failure of prosthetic vascular grafts, thereby potentially lowering healthcare costs and improving patient outcomes.
Tacalyx GmbH is an oncology company based in Berlin, Germany, specializing in the discovery and development of therapeutics targeting Tumor Associated Carbohydrate Antigens (TACAs) found on the surface of metastatic tumors. These carbohydrate antigens are unique to cancer cells, resulting from abnormal glycosylation processes that enhance tumor aggressiveness and immune evasion. Tacalyx leverages a technology platform that enables the synthesis and analysis of complex carbohydrate structures, facilitating the creation of novel immunotherapies. By focusing on these cancer-specific targets, Tacalyx aims to develop effective treatments for malignancies where existing therapies are inadequate, ultimately enhancing the ability of physicians to trigger robust anti-cancer responses.
Belyntic is a biotechnology company focused on advancing peptide purification and vaccine development. It has developed a purification kit that utilizes its innovative Catch & Release Technology, allowing for HPLC-free purification of chemically synthesized peptides. This technology aims to streamline and improve the peptide purification process. Additionally, Belyntic is engaged in the creation of novel vaccines designed to prevent viral diseases, bacterial infections, and cancer. The company offers ready-to-use research kits and engineered vaccines that activate T-cell immune responses, demonstrating significant potential in enhancing vaccine efficacy. By integrating artificial intelligence in its processes, Belyntic aims to identify pathogen-specific epitopes for self-adjuvant nano vaccine structures, supporting clients in the research, development, and production of peptide therapeutics for better health outcomes.
Pantherna Therapeutics is a privately-held biopharmaceutical Company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA drugs in the endothelium. Pantherna is based in Hennigsdorf (Brandenburg) close to Berlin, Germany.
DyNAbind GmbH, based in Dresden, Germany, is a biotech company specializing in drug discovery technologies using Dynamic DNA-Encoded Library (D-DEL) systems. Founded in 2015, the company focuses on developing regenerable biosensor technologies and offers services in DNA-encoded chemical library synthesis, selection, and decoding. DyNAbind's proprietary innovations enhance the drug discovery process by providing valuable insights into drug targetability and structure-activity relationship (SAR) analysis. The platform is designed to integrate seamlessly with fragment-based discovery methodologies, facilitating the identification of high-quality medicinal chemistry starting points for various protein targets. By expanding chemical space coverage, DyNAbind aims to support the healthcare industry in achieving more effective drug development outcomes.
miRdetect GmbH develops and markets n-vitro diagnostics. Its product includes miRcontrol GCT, a test kit for the detection of testicular cancer. The company also engages in research and development of new tests to detect cancers. miRdetect GmbH was founded in 2016 and is headquartered in Bremen, Germany.
NAVAN Technologies, Inc. is a pre-clinical stage biotechnology company based in South San Francisco, California, founded in 2016. The company focuses on developing and commercializing its proprietary NanoStraw platform technology, which facilitates direct access to the cytosol of cells. This innovative technology addresses a significant challenge in the field of cell and gene therapies by enabling the efficient and gentle delivery of various materials into difficult-to-transfect cells. Through its NanoStraw platform, NAVAN aims to enhance the capabilities of researchers in their efforts to advance therapeutic solutions.
cytena GmbH develops a laboratory device to separate single cells. Its products include singlecell printer, c.sight, b.sight, f.sight, and cartridge. The company offers its single cell printer technology for applications in cell line development, single cell genomic, and application development, including research and development aspects. The company was founded in 2014 and is headquartered in Freiburg, Germany with distribution networks in Europe, North America, India, Asia, and the United Kingdom. As per the transaction announced on August 5, 2019, cytena GmbH operates as a subsidiary of Cellink AB (publ).
4Gene GmbH, based in Langenpreising, Germany, specializes in the development and production of natural, biotechnologically engineered flavor and fragrance precursors. Founded in 2018, the company offers innovative solutions for various sectors, including food, cosmetics, industrial applications, and pharmaceuticals. Its unique products, marketed as FLAVOR-ON-DEMAND, are designed to be chemically stable and soluble in water, activating only when needed. This approach enhances the user experience for customers in the flavor and fragrance industry, providing tailored solutions that meet specific market demands. 4Gene serves a global clientele, positioning itself as a leader in the field of customer experience enhancement through advanced flavor and fragrance technologies.
PreOmics develops and provides innovative tools for customers around the world for mass spectrometry (MS)-based proteomics using cutting-edge technologies to support researchers in their protein analysis needs.
PreOmics is as a spin-off company from the proteomics research group of pioneer Matthias Mann at the Max-Planck Institute of Biochemistry. They at PreOmics develop and provide innovative technologies for mass spectrometry-based proteomics to make your research simply better. Their mission is to provide you with the best possible solutions and at the highest quality to achieve your results faster, easier and in a more robust manner than ever before.
denovoMATRIX GmbH, founded in 2018 and based in Dresden, Germany, specializes in the development and manufacturing of biomimetic coatings specifically designed for stem cell culture. The company's flagship products include screenMATRIX, a coating that enhances the adhesion, differentiation, migration, and organization of stem cells, and myMATRIX, a customized tissue cultureware microenvironment that supports the growth of stem cells and primary cells in serum-free media. These innovative products are utilized in various applications, including stem cell research, tissue modeling, and cell-based therapies, providing researchers with essential tools to advance their work and explore potential medical applications.
Amal Therapeutics SA is a biotech company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company focuses on the research and development of therapeutic vaccines for oncology, utilizing its proprietary cell penetrating peptide platform. Amal Therapeutics aims to create innovative therapeutic cancer vaccines and immunotherapies to enhance treatment options for cancer patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
Adivo GmbH is a veterinary biotechnology company based in Planegg, Germany, that specializes in the development of species-specific therapeutic antibodies for companion animals, particularly dogs. The company focuses on addressing serious diseases in pets and aims to extend its therapeutic offerings to other animal species. Adivo utilizes a fully synthetic, dog-specific drug library to select antibodies with optimal properties through phage display technology. As a spin-off of MorphoSys AG, Adivo benefits from extensive expertise in the development of human therapeutic antibodies, which the team applies to advance veterinary medicine.
advanceCOR GmbH is a drug development company based in Munich, Germany, specializing in therapeutics and diagnostics for heart and vascular diseases. Founded in 2000, the company focuses on creating personalized treatments and has developed several innovative products. Notable among these is Revacept, a human Fc fusion protein that inhibits the local activation of platelets at vascular injury sites. Additionally, advanceCOR offers COR-2, a recombinant protein that reduces foam cell generation and cholesterol uptake, and COR-3, which targets atherosclerotic plaques while binding to progenitor cells to promote plaque healing. The company’s product pipeline also includes therapies for acute arterial thrombosis, myocardial infarction, stroke, and transient ischemic attack, emphasizing its commitment to addressing serious cardiovascular conditions.
Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that serve as a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, focusing particularly on transcriptomics. By enabling single-cell barcoding in a test tube format, Scipio Bioscience's products facilitate advanced research in single-cell analysis, supporting laboratories in their scientific endeavors.
Amal Therapeutics SA is a biotech company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company focuses on the research and development of therapeutic vaccines for oncology, utilizing its proprietary cell penetrating peptide platform. Amal Therapeutics aims to create innovative therapeutic cancer vaccines and immunotherapies to enhance treatment options for cancer patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
stimOS GmbH develops a drug delivery biochemical procedure that initiates bone formation, anti inflammatory activity, and healing process. The company also develops technologies and procedures that refine, functionalize, and activate implant materials. It also offers research and development of implant materials and implant surfaces. stimOS GmbH was founded in 2015 and is based in Constance, Germany.
It develops the next generation of protein biomarker assays using a novel type of mass spectrometry-based immunoassays. SIGNATONE immunoassays are capable of detecting and quantifying protein biomarkers in humans and all pharmacologically relevant model species. Antibodies comprising epitopes of 4 amino acids are the key reagents of SIGNATOPE´s immunoassays. The short epitope allows us to establish quantitative assays for the same pro
TolerogenixX GmbH, based in Heidelberg, Germany, specializes in the development and commercialization of cell therapies aimed at immunosuppression. The company focuses on innovative solutions that address immune-related conditions, leveraging advancements in biotechnology to enhance patient outcomes. TolerogenixX's work contributes to the evolving landscape of therapeutic options in the field of immunology, positioning itself as a key player in the biotech sector.
NUMAFERM challenges this paradigm. We have developed a reliable, cost-efficient manufacturing process that enables the reduction of production costs dramatically (up to 1000x). How is it possible? Our process is based on a well-designed microorganism that converts simple nutrients to peptides. It is the first-in-place bioprocess that serves as a reliable platform for the production of peptides; independent of their sequence, length or functionality.
KSK Diagnostics GmbH, established in 2014 and based in Hamburg, Germany, specializes in the development of molecular point-of-care diagnostic assays aimed at diagnosing infectious diseases and cancer. The company utilizes isothermal amplification technology to create rapid tests that enable healthcare professionals to make timely diagnoses, often within 30 minutes, thereby facilitating prompt treatment decisions. In addition to its diagnostic assays, KSK Diagnostics offers customizable services, including the development of nucleic acid-based tests using real-time PCR or RT-PCR, as well as verification and validation studies and product enhancement services for other organizations in the healthcare sector. As a pioneer in this field, KSK Diagnostics is dedicated to improving patient-oriented diagnostics through innovative technologies.
PerformaNat GmbH is a Berlin-based company that specializes in the development of feed additives and dietetic supplements for livestock. Founded in 2015, the company aims to enhance the physiological processes of animal metabolism through innovative products. PerformaNat focuses on utilizing natural substances to address challenges in advanced animal nutrition, particularly optimizing calcium intake for livestock. By improving animal health and promoting efficient nutrient utilization, the company enables livestock owners and milk production enterprises to reduce feeding costs while enhancing overall productivity.
SciRhom GmbH is a biotech company focused on the preclinical and early clinical development of novel biopharmaceuticals aimed at treating life-threatening autoimmune diseases. Founded in 2016 through collaboration between academic and industry scientists with expertise in antibody development, SciRhom leverages extensive research and a network of specialists to advance its therapeutic offerings. The company develops therapeutic antibodies targeting iRhom2, a significant modulator of key pro-inflammatory signaling pathways, including TNF-alpha. This approach seeks to enhance treatment options for patients suffering from severe autoimmune conditions, particularly those affecting the skin and intestinal barriers.
Rigontec GmbH is a biopharmaceutical company specializing in RNA-based immunotherapeutics aimed at treating cancer and viral diseases. Founded in 2014 and based in Planegg, Germany, the company focuses on developing compounds that activate the immune receptor retinoic acid-inducible gene I (RIG-I), specifically through its lead product, ImOl100. This compound acts as a minimal mimic of the naturally occurring 3pRNA motif found in viral RNAs, stimulating the immune response effectively. Rigontec's approach circumvents common challenges faced by traditional cancer therapies, such as vaccines and checkpoint inhibitors, by targeting RIG-I pathways to induce tumor cell death and promote long-term immunity. In 2017, Rigontec became a subsidiary of Merck & Co., Inc., enhancing its capabilities in the field of immuno-oncology.
CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intends to extend the benefits of cryoenergy to the problem of diseased coronary arteries.
Thermosome GmbH is a biopharmaceutical company based in Planegg, Germany, focused on developing innovative drug candidates for cancer treatment. The company utilizes a proprietary drug delivery technology that operates through a mechanism known as intravascular drug release. This platform aims to enhance the efficacy and reduce the side effects of chemotherapy, particularly for patients with locally advanced solid tumors. Thermosome's lead product is currently in the final pre-clinical development stage, and the company has built its foundation on promising preclinical results obtained from research conducted at the Max Planck Institute for Biophysical Chemistry and the University Hospital of Ludwig-Maximilians-Universität Munich. Since commencing its operational activities in late 2015, Thermosome has been dedicated to advancing treatment options for cancer patients through targeted therapeutic approaches.
Amal Therapeutics SA is a biotech company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company focuses on the research and development of therapeutic vaccines for oncology, utilizing its proprietary cell penetrating peptide platform. Amal Therapeutics aims to create innovative therapeutic cancer vaccines and immunotherapies to enhance treatment options for cancer patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
SeNostic is a diagnostics company focused on developing innovative in vitro diagnostic tests for neurodegenerative disorders. The company aims to provide precise and accurate early differential diagnoses for various neurodegenerative conditions, enhancing the ability to identify specific diseases. SeNostic also specializes in offering biochemicals for neuroscience research and has created a novel method to amplify and characterize disease-specific protein aggregates found in tissues and body fluids. This approach enables better patient outcomes by facilitating timely and appropriate treatment for those affected by neurodegenerative diseases.
Computomics is a team of world-leading experts in plant research and bioinformatics, offering next-generation sequencing (NGS) analyses for agriculture biotech companies and crop scientists. Whether you are concerned with crop improvement, seed production or plant protection, Computomics helps navigate the complexities of grain, vegetable, fruit and other genomes. Our advanced bioinformatics services provide our customers with quality NGS data interpretation from state-of-the-art genomics tools and technologies. Let us help you achieve your research goals.
Venneos GmbH, founded in 2014 in Stuttgart, Germany, is a high-tech startup that specializes in developing a silicon chip-based imaging system for the label-free analysis of biological cells. The company's flagship product, the CAN-Q, utilizes a technology known as CAN-Spectroscopy, which enables researchers to observe cellular changes, particularly in areas such as cell adhesion, that are not detectable with conventional methods. This innovative imaging system provides valuable insights for applications in tumor biology, immunology, and pharmacology, serving customers in both academia and the pharmaceutical and biotechnology sectors. As a spin-off from the Max Planck Society, Venneos aims to advance the capabilities of biological analysis through its cutting-edge technology.
cytena GmbH develops a laboratory device to separate single cells. Its products include singlecell printer, c.sight, b.sight, f.sight, and cartridge. The company offers its single cell printer technology for applications in cell line development, single cell genomic, and application development, including research and development aspects. The company was founded in 2014 and is headquartered in Freiburg, Germany with distribution networks in Europe, North America, India, Asia, and the United Kingdom. As per the transaction announced on August 5, 2019, cytena GmbH operates as a subsidiary of Cellink AB (publ).
oncgnostics GmbH develops molecular assays based on epigenetic biomarkers which allows early and reliable cancer diagnostics. It develops GynTect, which enables reliable and fast diagnosis of cervical cancer and pre-cancerous stages; and in vitro diagnostic (IVD) tests for screening, therapeutic decision making, and follow-up care in cancer diagnostics. The company was founded in 2012 and is based in Jena, Germany.
Rigontec GmbH is a biopharmaceutical company specializing in RNA-based immunotherapeutics aimed at treating cancer and viral diseases. Founded in 2014 and based in Planegg, Germany, the company focuses on developing compounds that activate the immune receptor retinoic acid-inducible gene I (RIG-I), specifically through its lead product, ImOl100. This compound acts as a minimal mimic of the naturally occurring 3pRNA motif found in viral RNAs, stimulating the immune response effectively. Rigontec's approach circumvents common challenges faced by traditional cancer therapies, such as vaccines and checkpoint inhibitors, by targeting RIG-I pathways to induce tumor cell death and promote long-term immunity. In 2017, Rigontec became a subsidiary of Merck & Co., Inc., enhancing its capabilities in the field of immuno-oncology.
4 Animals AlsterScience GmbH, located in Hamburg, Germany, specializes in the development of biologic drugs and feed supplements for animals aimed at enhancing immune function. The company's innovative products address various health challenges in animals, including viral diseases, tumors, inoculations, and cell therapies. By providing these biologics, 4 Animals AlsterScience GmbH seeks to combat the growing issue of resistance to conventional drugs, offering effective alternatives to improve animal health and welfare.
i3 membrane will assist you creating new membranes for next life science. The qualities inertness, flexibility, durability and conductivity of i3 membranes are predestinated to meet current and future challenges to ensure success in your research, development and production.
Photonics Healthcare is a medical device company specializing in the development and commercialization of clinical monitors for measuring cellular oxygen levels. Founded in 2009 and based in Garching, Germany, the company offers its flagship product, the COMET Monitor, which non-invasively assesses cellular oxygen metabolism, including both oxygen availability and consumption. This technology is crucial for healthcare providers, enabling them to monitor patients' tissue oxygen levels in real time, particularly in situations where oxygen supply is compromised or cellular metabolism is affected. Additionally, Photonics Healthcare engages in contract research programs to further advance its offerings in the medical monitoring field.
PS Biotech GmbH, established in May 2013 as a spin-off from RWTH Aachen University and DWI at RWTH Aachen e.V., focuses on enhancing microbial production processes through innovative feeding techniques. The company's primary product is a specialized feed plate that addresses challenges associated with traditional batch feeding methods, such as the crabtree effect, excess metabolism, and catabolite repression. This technology allows producers to scale up their production processes more efficiently and effectively. The foundation of PS Biotech was supported by experienced staff from AGIT and received financial backing from High Tech Gründerfonds II, reinforcing its commitment to advancing biotechnological applications in high-throughput screenings.
evocatal develops and produces enzymes and fine chemicals for the chemical and pharmaceutical industries. We offer a catalog of enzymes (evozymes) as well as and tailor-made biocatalysts for specific industrial applications. Our biocatalysts are applied in various consumer goods industries, including the production and refinement of textiles, adhesives, detergents, nutrition and cosmetics. Our customers regard evocatal as a premium provider of high quality chiral building blocks (evochemicals): from a few grams to several tons. At evocatal we have also continued to focus on providing efficient biocatalytic processes as a service (evoservices). Do you need a biocatalyst for a very specific application? Contact us!
Rodos BioTarget GmbH is a biopharmaceutical company based in Hanover, Germany, founded in 2008. The company specializes in developing advanced drug delivery technologies, notably its patented TargoSphere platform. This nanocarrier system is designed to deliver a variety of therapeutic agents directly to antigen-presenting cells, thereby enhancing the immune response against infectious diseases caused by viruses, such as Hepatitis C and HIV, as well as bacterial infections like Tuberculosis and MRSA. Rodos BioTarget also offers TargoBiotics, which includes antibiotics for intracellular treatment, and TargoVir for viral infections. Additionally, the TargoSphere technology has potential applications in managing chronic inflammation, cancer, allergies, and autoimmune diseases by addressing imbalances in immune responses. The company's innovations aim to improve drug stability, biodistribution, and therapeutic efficacy.
CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intends to extend the benefits of cryoenergy to the problem of diseased coronary arteries.
Bionic Robotics GmbH (formerly BioRob) - the smarter solution for flexible automation in small and medium enterprises.
InnoCyte - Technologies for automated Cell Culture. They have the strong belief that automated cell culture could be of inestimable value for cell processing in labs all over the world. InnoCyte brings automated cell culture to the masses - within a benchtop designed, reliable and affordable device.
GeneQuine Biotherapeutics designs and develops gene therapies for its clients. The therapies developed by the company aim to treat osteoarthritis. Its product portfolio consists of GQ-201, GQ-202, and GQ-203. GeneQuine Biotherapeutics was founded in 2011 by Stanislav Plutizki and Kilian Guse.
JeNaCell GmbH, founded in 2012 and based in Jena, Germany, specializes in biotechnology by developing and manufacturing bio-technologically derived cellulose. The company has patented a unique technology for the continuous production of high-performance biomaterials featuring natural nanostructures. These materials have a defined shape and controllable structural design, allowing clients to create innovative products across various sectors, including medicine, cosmetics, technology, and pharmaceuticals. JeNaCell's solutions are particularly beneficial in medical applications, helping to protect skin from chronic wounds and enhancing treatments in aesthetic dermatology.
AYOXXA Biosystems GmbH is a biotechnology company based in Cologne, Germany, with additional offices in Singapore and Boston, Massachusetts. Founded in 2010, AYOXXA specializes in life science tools, particularly through its proprietary technology platform for multiplexed protein analysis. The company has developed an innovative biochip technology that enables the simultaneous measurement of multiple protein markers associated with various health conditions, including cancer, allergies, cardiovascular diseases, and infectious diseases. AYOXXA's platform utilizes an in-situ encoded bead array, facilitating the identification and quantification of proteins and biomolecular analytes. This advanced approach to biomarker analysis positions AYOXXA at the forefront of diagnostic technology, allowing for comprehensive testing in a single assay.
Cysal GmbH is a biotechnology company based in Münster, Germany, established in 2012. The company specializes in developing, optimizing, and licensing fermentation technology solutions for biopolymers and low-molecular weight compounds, including dipeptides. Cysal provides a variety of services, including fermentation technology development and the selection of microbial strains, aimed at enhancing the production processes for its clients. By focusing on microbial metabolic diversity and fermentation processes, Cysal enables researchers to adopt more sustainable methods for producing specialty and base commodities, replacing traditional chemical approaches. The company collaborates with a network of partners and distributors both in Germany and internationally to deliver its innovative solutions.
Subitec was founded in 2000 as a spin-off of the Fraunhofer Institute for Interfacial and Biotechnology (IGB). In the run-up to the founding, scientists at IGB had already been dealing with the subject of microalgae since 1995. In 2007, operational business was started and the first investors were sought after.
Epivios GmbH, based in Düsseldorf, Germany, specializes in molecular diagnostics aimed at the early detection of bladder and prostate cancer. Established in 2011 as a spin-off from the Heinrich Heine University of Düsseldorf, the company is led by an interdisciplinary team of doctors and biologists who have been advancing innovative epigenetic techniques for cancer diagnosis since 2009. Epivios has developed a unique epigenetic platform that features a standardization tool, allowing for the comparison of samples with varying genetic backgrounds. This groundbreaking technology enhances the analysis of genomic sequences, facilitating improved diagnostic capabilities for cancer physicians.
t-cell Europe is a medical company that develops T-cell-based therapies based on IP-protected platform technology.
oncgnostics GmbH develops molecular assays based on epigenetic biomarkers which allows early and reliable cancer diagnostics. It develops GynTect, which enables reliable and fast diagnosis of cervical cancer and pre-cancerous stages; and in vitro diagnostic (IVD) tests for screening, therapeutic decision making, and follow-up care in cancer diagnostics. The company was founded in 2012 and is based in Jena, Germany.
ZIM Plant Technology markets crop water sensor technology solutions that are able to measure the water supply of leaves of intact plants. Its solutions are used in high-precision irrigation systems to improve yields and water use efficiency. ZIM Plant Technology was acquired by Yara in November 2013. ZIM Plant Technology was founded in 2010.
OakLabs GmbH is a research firm based in Hennigsdorf, Germany, specializing in integrated business solutions for the biotechnology and medical technology sectors. Founded in 2011 by Martina Schad, the company offers a range of services including custom SNP genotyping, DNA marker analysis, and consulting. Its expertise encompasses biocomputing, which involves sequence analysis, genomic selection, and biomolecule simulation, as well as MyArray services that include XL-design development and RNA/DNA sample hybridization. OakLabs also develops dedicated algorithms for the identification and analysis of DNA markers, linking them to specific traits in various sequenced organisms. Additionally, the company provides training, maintenance, and algorithm enhancement services to support its clients in the field.
CorTec GmbH, based in Freiburg, Germany, specializes in neurotechnology, focusing on the measurement and stimulation of brain activity. The company has developed the CorTec Brain Interchange, a brain pacemaker technology designed to treat neurological diseases through an implantable system that can record brain activity and deliver stimulation in a closed-loop manner. This innovative approach enhances the capabilities of physicians in managing neurological conditions and improving patient outcomes. In addition to its primary device, CorTec provides ready-to-use components and custom design solutions tailored to specific client requirements. Founded in 2010, the company is actively involved in advancing neurotherapies, conducting preclinical neuroscientific research, and supporting clinical diagnostics and research efforts.
Microstim GmbH develops a tissue and function maintaining implantable myostimulator designed to assist the heart. Particular strengths of Microstim GmbH are the microcontroller acquisition and processing of data, control of cardiac and muscle stimulator impulses, and wireless “in-bodyâ€-communication. At the national business plan contest “Science4Life†in 2008, Microstim GmbH was one of ten winners in the concept phase category.
Lipocalyx GmbH, a Wolfen, Germany-based newly founded company focused on development of transfection reagents for siRNA based on innovative polymers.
Lophius Biosciences GmbH operates as a research and development partner for immunology/T cell solutions from research tools and services to diagnostic systems. It offers diagnostic kits, ready-to-use elispot kits, elispot plates, antibodies, stimulants, and supplemental material; and sample access and handling, antigen, immune assay development and performance, IVD, and better therapy services. The company was founded in 2002 and is based in Regensburg, Germany.
NonWoTecc GmbH was founded with the financial support of High-Tech Gründerfond (HTGF) and Rheinland Venture Capital Fond (RVC) in February of 2007. The goal was to develop a newly designed vascular prosthesis with improved biocompatible and bio-stable properties. NonWoTecc GmbH was one of only seven companies which received a commitment for financial support from HTGF in 2006.
Viral Vector Technology as key enabler for innovative therapeutics. Viral vectors are a tool commonly used by molecular biologists to deliver genetic material into cells. This technique enables research of gene function and innovative therapeutics designed to correct defective genes and cancer. These technologies also assist in the discovery of new drug, food and cosmetic compounds. SIRION is a global leader in viral vector technology for gene modification of mammalian cells. Along with custom services, the company stands ready to outlicense its unique technologies. An initial target currently being pursued by one of SIRION's partners is a gene therapeutic for cervical cancer. The company started business in 2007 and since then has been changing the paradigm of viral vector supplies. Specifically, all commonly applied vector types are now available within a matter of weeks - adenovirus, adeno-associated virus (AAV) and lentivirus - and a full range of virus related services is at your fingertips spanning from particle production to virus driven cell modelling, all at highest titers and in quantities required for preclinical, clinical and animal testing. The company is easily accessible with presence in Munich, Tokyo, New Hampshire and Tel Aviv. Commercial arrangements range from fee-for-service over exclusive rights on single clones all the way to milestone & licensing arrangements. The business model proves successful: an annual 70% growth since 2007 and experienced in more than 500 projects for both the academic and industry sector. The company is privately held and has over the years raised funds from 8 investors both private and government. In order to support further growth and to benefit from technology development in this exciting industry, the company welcomes new investors. Please contact Management for further information about the company and its future plans.
m2p-labs was founded in November 2005 as a spin off of the department of biochemical engineering and the institute of materials in electrical engineering of the RWTH Aachen University. m2p-labs is a biotechnology company focused on the support of micro reaction solutions in biochemical engineering. The company offers a unique quantitative micro reactor cultivation system which is applicable in high content screening and bioprocess development.
TRANSCATHETER TECHNOLOGIES is developing a unique aortic valve implantation system that will increase the safety and durability of aortic valve implantation. The TRINITY repositionable transcatheter aortic valve system is at the forefront of next-generation transcatheter valve implantation technology. In the near future, transcatheter valve implantation will become the preferred therapy for aortic valve implantation, and TRANSCATHETER TECHNOLOGIES‘ goal is to provide the most advanced technology available.
GILUPI GmbH, a Potsdam, Germany-based company that develops and produces medical devices for the in vivo isolation of rare cells out of the circulating blood.
Heppe Medical Chitosan GmbH, based in Halle, Germany, specializes in the development, production, and sale of biopolymers primarily for the cosmetic and pharmaceutical sectors. Founded in 2005, the company focuses on chitin, chitosan, and their derivatives, providing high-quality raw materials that adhere to Good Manufacturing Practice (GMP) standards. In addition to conventional chitin and chitosan products, Heppe Medical Chitosan also creates nanoparticulate forms of these biopolymers, catering to diverse applications within its target industries. The company was formerly known as Katja Heppe Medical Chitosan and adopted its current name in 2006.
Biametrics specializes in providing innovative research and development services aimed at the academia, pharmaceutical, biotechnology, and diagnostic markets. The company's products focus on label-free detection systems that characterize biomolecular interactions, offering valuable kinetic and thermodynamic data, including affinity measurements and specificity information. Biametrics' technology enables enhanced data evaluation for applications in diagnostics and process analytics, allowing clients to gain insights into biomolecular behavior with unmatched performance in throughput and versatility.
ChromoTek GmbH develops immunologic research and detection reagent and tools for proteomics and cell biology. The company was founded in 2008 and is based in Planegg-Martinsried, Germany.
evocatal develops and produces enzymes and fine chemicals for the chemical and pharmaceutical industries. We offer a catalog of enzymes (evozymes) as well as and tailor-made biocatalysts for specific industrial applications. Our biocatalysts are applied in various consumer goods industries, including the production and refinement of textiles, adhesives, detergents, nutrition and cosmetics. Our customers regard evocatal as a premium provider of high quality chiral building blocks (evochemicals): from a few grams to several tons. At evocatal we have also continued to focus on providing efficient biocatalytic processes as a service (evoservices). Do you need a biocatalyst for a very specific application? Contact us!
ZEDIRA GmbH, a biopharmaceutical company, develops drugs to treat celiac disease. It offers TG6, a neuronal transglutaminase marker used in detecting neurological disorders caused by gluten. The company also produces and markets specialty reagents to assist investigators who are studying celiac disease; and develops active ingredients and celiac disease diagnostic antigens. ZEDIRA GmbH also provides proteases, assays, substrates, antibodies, inhibitors, and autoantibody detection ELISA-Kits. The company was founded in 2007 and is based in Darmstadt, Germany.
Lophius Biosciences GmbH operates as a research and development partner for immunology/T cell solutions from research tools and services to diagnostic systems. It offers diagnostic kits, ready-to-use elispot kits, elispot plates, antibodies, stimulants, and supplemental material; and sample access and handling, antigen, immune assay development and performance, IVD, and better therapy services. The company was founded in 2002 and is based in Regensburg, Germany.
PEPperPRINT GmbH, based in Heidelberg, Germany, specializes in high-density peptide arrays and offers a versatile peptide microarray platform known as PEPperCHIP. This platform is designed for various applications, including proteome interaction analysis, antibody profiling, epitope mapping, and the study of sequence variations. The company also provides PEPperSCREEN services, which facilitate the identification and optimization of peptides and peptidomimetics for research, diagnostics, and therapeutic purposes. These services encompass antibody decoding, enzyme profiling, protein biomarker discovery, drug development, and the creation of functional mimetics. Additionally, PEPperPRINT offers PEPperSlide, a tool for the immobilization of biomolecules and for conducting microarray experiments and immunoassays. Founded in 2001, PEPperPRINT is dedicated to advancing peptide research through customizable and cost-effective solutions.
TRANSCATHETER TECHNOLOGIES is developing a unique aortic valve implantation system that will increase the safety and durability of aortic valve implantation. The TRINITY repositionable transcatheter aortic valve system is at the forefront of next-generation transcatheter valve implantation technology. In the near future, transcatheter valve implantation will become the preferred therapy for aortic valve implantation, and TRANSCATHETER TECHNOLOGIES‘ goal is to provide the most advanced technology available.
Intana Bioscience GmbH is a customized assay development, screening and target validation company that uses fluorescence cross-correlation spectroscopy. It offers its users with fast assay development time, physiological measurement conditions, and comprehensive readouts. Technologies used in the company are fluorescence correlation spectroscopy, fluorescence cross-correlation spectroscopy, and FCS and FCCS measurements. Intana Bioscience GmbH is a Germany-based company that was founded in 2008 by Stefan Hannus and Frank Becker.
Rodos BioTarget GmbH is a biopharmaceutical company based in Hanover, Germany, founded in 2008. The company specializes in developing advanced drug delivery technologies, notably its patented TargoSphere platform. This nanocarrier system is designed to deliver a variety of therapeutic agents directly to antigen-presenting cells, thereby enhancing the immune response against infectious diseases caused by viruses, such as Hepatitis C and HIV, as well as bacterial infections like Tuberculosis and MRSA. Rodos BioTarget also offers TargoBiotics, which includes antibiotics for intracellular treatment, and TargoVir for viral infections. Additionally, the TargoSphere technology has potential applications in managing chronic inflammation, cancer, allergies, and autoimmune diseases by addressing imbalances in immune responses. The company's innovations aim to improve drug stability, biodistribution, and therapeutic efficacy.
PluriSelect develops biotechnical devices and supplies focused on efficient tools for cell and protein separation. The company's products facilitate the isolation of cells from whole blood, buffy coat, cell culture, and other complex biological liquids, as well as the extraction of specific targets from unbound materials. By providing these solutions, PluriSelect supports researchers in academic science, helping them achieve high-quality results while saving time and resources in their routine tasks.
Microstim GmbH develops a tissue and function maintaining implantable myostimulator designed to assist the heart. Particular strengths of Microstim GmbH are the microcontroller acquisition and processing of data, control of cardiac and muscle stimulator impulses, and wireless “in-bodyâ€-communication. At the national business plan contest “Science4Life†in 2008, Microstim GmbH was one of ten winners in the concept phase category.
Lophius Biosciences GmbH operates as a research and development partner for immunology/T cell solutions from research tools and services to diagnostic systems. It offers diagnostic kits, ready-to-use elispot kits, elispot plates, antibodies, stimulants, and supplemental material; and sample access and handling, antigen, immune assay development and performance, IVD, and better therapy services. The company was founded in 2002 and is based in Regensburg, Germany.
HAPILA GmbH, based in Gera, Germany, specializes in pharmaceutical and chemical development services tailored for the pharmaceutical and biotech industries. Founded in 2007, the company offers a comprehensive range of solutions, including the purification and physical conditioning of active pharmaceutical ingredients, as well as consulting on regulatory affairs and quality control of raw materials and drug substances. HAPILA is adept at developing analytical methods, cleaning validation, and the certification of reference standard substances. Its expertise extends to the research, development, and manufacture of sophisticated active ingredients, supporting clients through various stages, from process development and preclinical testing to clinical studies and the supply of active ingredients for marketed products. The company emphasizes flexibility and open communication in its partnerships, ensuring tailored solutions that meet customer needs while adhering to high ethical standards.
Corimmun is a clinical drug developing company located in Martinsried near Munich, Germany, and is focused on novel therapeutics and diagnostics for heart and vascular diseases. Corimmun's activities and experiences comprise all steps from research to drug development and commercialization.